Biotech Values

[ghmm]

10K reports do not have to disclose every business relationship—only the ones considered material.
Not an expert in disclosure and not even doubting that there are other 3rd party royalties or even a big bonus to some Doc who invented it... but could it be just a wording by a new CFO who has been there just a couple of months (old one left to become CEO at a startup company)? In particular I believe in the call when talking about US royalty obligation (I believe they said to Array) it was stated it would be shared equally. When I make notes I'll pay particular attention to see if it was RE Array or general (While possible I don't think Roche would pay 1/2 Royalties to Array but not other 3rd parties).

Not that a few percent x-US is meaningless (based on potential market opp.) but either way Array gets peanuts and InterMune still gets potentially extremely nice profit share in US and meaningful royalty x-US